PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Cambridge Healthtech Institute

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Cambridge Healthtech Institute Announces its Inaugural Biologics Formulation & Delivery Summit - Shaping the Future of Delivering Biotherapeutics - What's on the Horizon - CHICorporate.com / HealthTech.com
Cambridge Healthtech Institute Announces its Inaugural Biologics Formulation & Delivery Summit

 

NewswireToday - /newswire/ - Needham, MA, United States, 2014/01/10 - Shaping the Future of Delivering Biotherapeutics - What's on the Horizon - CHICorporate.com / HealthTech.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Cambridge Healthtech Institute (CHI) today announced it will host its inaugural "Biologics Formulation & Delivery Summit" -- an international forum for the pharmaceutical and device industries to identify courses of action in biotherapeutics delivery on May 5-7, 2014 at the World Seaport Trade Center in Boston, MA. This two-part summit will discuss various formulation and device-based approaches for designing physiologically relevant, patient friendly, targeted biologics products.

Part 1: Formulation Strategies for Improved Delivery of Biologics (May 5-6)
Overcoming Challenges in Injectable Drug Delivery via Breakthrough Delivery and Device Strategies is the main theme of this conference with a keynote presentation by Julia Rashba-Step, Ph.D., Senior Director, Novel Delivery Technologies, Pfizer, Inc., will educate the audience on the future trends on biotherapeutics and importance of drug delivery in commercial, clinical differentiation and also the need for enabling technologies. In addition, strategic plans for current and future delivery reflective of needs of Pfizer's biotherapeutics portfolio will be discussed.

Part 2: New Technologies for Biologics Delivery and Targeting (May 6-7)
Driving Innovation Through New Targets, Effective Tools, Next-Gen and Alternate Delivery Technologies is the main theme of this conference with a keynote presentation by Omid Farokhzad, M.D., Associate Professor, Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital and Harvard Medical School, on the design and optimization of polymeric nanoparticles for medical applications, which formed the foundation for the clinical translation of the first-in-human targeted and controlled-release nanoparticles, BIND-014 and SEL-068.

Advances in molecular biology and biotechnology have allowed for the large-scale production of effective and potent biotherapeutic drugs. Major research issues in protein/peptide delivery include the stabilization of proteins in delivery devices and the design of appropriate target-specific carriers. "This summit will be an excellent forum for focused discussions, initiate new collaborations, socialize and interact with colleagues from around the world who are facing similar challenges and utilizing compelling strategies. CHI looks forward to adding this Summit to its portfolio of scientific events scheduled for 2014," states CHI conference director, Nandini Kashyap.

The rest of the summit includes talks by MedImmune, Allergan, Shire, MannKind, Novartis, Northeastern University, Duke University, to name a few. Plus, delegates may choose from three interactive short courses geared towards turning their technologies into successful patient-friendly products. The summit is co-located with PEGS: the essential protein engineering summit where 1600+ delegates and 100+ exhibitors will be in attendance. Delegates have access to a shared exhibit hall with the PEGS attendees, joint exhibit hall reception and networking breaks.

The Summit offers student fellowship awards to full-time graduate students and Ph.D. candidates. For further information, to apply for a student fellowship, or to register, visit healthtech.com/biologics-delivery.

To receive a press pass or arrange an interview with a speaker, email Lisa Scimemi at lscimemi[.]healthtech.com.

About Cambridge Healthtech Institute (CHI)

Cambridge Healthtech Institute (chicorporate.com), founded in 1992, is the industry leader in providing superior quality scientific information to eminent researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, and Cambridge Healthtech Media Group.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Cambridge Healthtech Institute

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Cambridge Healthtech Institute Announces its Inaugural Biologics Formulation & Delivery Summit

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: James Prudhomme - HealthTech.com 
781-972-5400 jprudhomme[.]healthtech.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cambridge Healthtech Institute securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Cambridge Healthtech Institute / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)